Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.36 |
| ▸ | CNR1 | P21554 | 8/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.32 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20066540 | 0.86 | S1PR4 (0.32) | CNR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL23692666 | 0.86 | S1PR4 (0.32) | CNR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL19928210 | 0.86 | S1PR4 (0.32) | CNR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL26372213 | 0.77 | HMGCR (0.34) | — | |
| SCHEMBL22023802 | 0.72 | CNR2 (0.36) | CNR2CNR1 | |
| SCHEMBL22023644 | 0.72 | CNR2 (0.40) | CNR2CNR1 | |
| SCHEMBL21982478 | 0.72 | CNR2 (0.31) | CNR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL25619200 | 0.72 | S1PR4 (0.30) | S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL25469249 | 0.70 | CNR2 (0.33) | CNR2CNR1 | |
| SCHEMBL18857358 | 0.70 | CNR2 (0.33) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| US-20230203000-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | CNR2 1551/4885CNR1 1424/4885NR1H4 2850/4885 |
| US-20230203000-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, RNASE1 | CNR2 4690/4885CNR1 4480/4885NR1H4 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.